Method of determining dose of erythropoiesis-stimulating agent

Patent metadata

Field	Value
Publication number	US-10496794-B2
Application number	US-201514960801-A
Country	US
Kind code	B2
Filing date	Dec 7, 2015
Priority date	Jun 13, 2013
Publication date	Dec 3, 2019
Grant date	Dec 3, 2019

Abstract

A method of determining an ESA dose, which allows a hemoglobin concentration in the blood to be stably maintained at a target value, and which can decrease a range of fluctuation of the hemoglobin concentration with respect to the target value. The method comprises the steps of: setting the target value of the hemoglobin concentration in the blood; calculating a target value of a hemoglobin production rate which allows the hemoglobin concentration to reach the target value; calculating a serum ESA concentration which allows the hemoglobin production rate to reach the target value, from a relationship between the hemoglobin production rate and the ESA concentration; and calculating an amount of administration of an ESA which gives the serum ESA concentration, from a relationship between the ESA concentration and the amount of administration of the ESA, to determine an ESA dose which allows the hemoglobin concentration to reach the target value.

First claim

The invention claimed is:

1. A method of treating a patient, comprising:
a first step of setting a target value of a hemoglobin concentration in blood;
a second step of calculating a target value of a hemoglobin production rate which allows the hemoglobin concentration to reach said target value;
a third step of calculating a calculated concentration of an erythropoiesis-stimulating agent, which calculated concentration allows the hemoglobin production rate to reach said target value, from a relationship between the hemoglobin production rate at a present moment and the concentration of the erythropoiesis-stimulating agent up to the present moment;
a fourth step of calculating an amount of administration of the erythropoiesis-stimulating agent, which amount gives said calculated concentration of the erythropoiesis-stimulating agent, from a relationship between the concentration of the erythropoiesis-stimulating agent and its amount of administration, to determine a dose of the erythropoiesis-stimulating agent, which dose allows the hemoglobin concentration to reach said target value; and
a fifth step of administering to said patient said dose of the erythropoiesis-stimulating agent;
said third step comprising the steps of:
obtaining the hemoglobin production rate at a present measurement of the hemoglobin concentration;
calculating a mean concentration of the erythropoiesis-stimulating agent in a length of time between a last measurement and the present measurement of the hemoglobin concentration, from an amount of the erythropoiesis-stimulating agent administered between the last and present measurements of the hemoglobin concentration;
calculating a value a indicating a degree of sensitivity of hemoglobin production with respect to the concentration of the erythropoiesis-stimulating agent, from said mean concentration of the erythropoiesis-stimulating agent and said hemoglobin production rate; and
calculating said calculated concentration of the erythropoiesis-stimulating agent from said value a and said target value of the hemoglobin production rate.

2. The method of determining the dose of the erythropoiesis-stimulating agent according to claim 1 , wherein said target value of the hemoglobin production rate is obtained by dividing a target total amount of hemoglobin by an average lifespan of red blood cells.

3. The method of treating a patient according to claim 1 , wherein:
the concentration of the erythropoiesis-stimulating agent is calculated in said third step by using a relational expression representing that the hemoglobin production rate is proportional to a logarithmic value of the concentration of the erythropoiesis-stimulating agent.

4. The method of determining the dose of the erythropoiesis-stimulating agent according to claim 1 , wherein the concentration of the erythropoiesis-stimulating agent is calculated in said third step by using a relational expression representing that the hemoglobin production rate is linearly proportional to the concentration of the erythropoiesis-stimulating agent.

5. The method of determining the dose of the erythropoiesis-stimulating agent according to claim 1 , wherein the hemoglobin production rate at the present measurement of the hemoglobin concentration is obtained according to the following formula (5b):
G real= CHg 2× BV/TR +( CHg 1× BV−CHg 2× BV )/ TT   (5b)

wherein Greal denotes the hemoglobin production rate in an unstable state, CHg 1 denotes the hemoglobin concentration at a given point of time, CHg 2 denotes the hemoglobin concentration measured before the given point of time, BV denotes a blood volume, TR denotes an average red-blood-cell lifespan and TT denotes the number of days between the two points of time.

6. A method of treating a patient, comprising:
a first step of setting a target value of a hemoglobin concentration in blood;
a second step of calculating a target value of a hemoglobin production rate which allows the hemoglobin concentration to reach said target value;
a third step of calculating a concentration of an erythropoiesis-stimulating agent, which concentration allows the hemoglobin production rate to reach said target value, from a relationship between the hemoglobin production rate at a present moment and the concentration of the erythropoiesis-stimulating agent up to the present moment;
a fourth step of calculating an amount of administration of the erythropoiesis-stimulating agent, which amount gives said concentration of the erythropoiesis-stimulating agent, from a relationship between the concentration of the erythropoiesis-stimulating agent and its amount of administration, to determine a dose of the erythropoiesis-stimulating agent, which dose allows the hemoglobin concentration to reach said target value; and
a fifth step of administering to said patient said dose of the erythropoiesis-stimulating agent;
said third step comprising calculating said concentration of an erythropoiesis-stimulating agent according to the following formula (12b):
target MC ESA =exp(target G/a )  (12b)

wherein target MC ESA denotes a mean concentration of the erythropoiesis-stimulating agent which allows the hemoglobin concentration to reach said target value, target G denotes said target value of the hemoglobin production rate, and a denotes a value indicating a degree of sensitivity of the hemoglobin production with respect to the concentration of the erythropoiesis-stimulating agent.

7. The method of determining the dose of the erythropoiesis-stimulating agent according to claim 1 , wherein the value a indicating a degree of sensitivity of hemoglobin production with respect to the concentration of the erythropoiesis-stimulating agent is calculated from said mean concentration of the erythropoiesis-stimulating agent and said hemoglobin production rate according to the following formula (10b):
a=G /ln( MC ESA )  (10b)

wherein G is the hemoglobin production rate and MC ESA denotes said mean concentration of the erythropoiesis-stimulating agent.

8. A method of treating a patient, comprising:
a first step of setting a target value of a hemoglobin concentration in blood;
a second step of calculating a target value of a hemoglobin production rate which allows the hemoglobin concentration to reach said target value;
a third step of calculating a concentration of an erythropoiesis-stimulating agent, which concentration allows the hemoglobin production rate to reach said target value, from a relationship between the hemoglobin production rate at a present moment and the concentration of the erythropoiesis-stimulating agent up to the present moment;
a fourth step of calculating an amount of administration of the erythropoiesis-stimulating agent, which amount gives said concentration of the erythropoiesis-stimulating agent, from a relationship between the concentration of the erythropoiesis-stimulating agent and its amount of administration, to determine a dose of the erythropoiesis-stimulating agent, which dose allows the hemoglobin concentration to reach said target value; and
a fifth step of administering to said patient said dose of the erythropoiesis-stimulating agent;
said second step comprising calculating said target value of a hemoglobin production rate according to the following formula (11):
target G =target CHg×BV/TR   (11)

wherein target G denotes said target value of the hemoglobin production rate, target CHg denotes said target value of the hemoglobin concentration, BV denotes a blood volume and TR denotes an average red-blood-cell lifespan.

9. The method of determining the dose of the erythropoiesis-stimulating agent according to claim 1 , wherein said mean concentration of the erythropoiesis-

Assignees

• Nipro Corp

Inventors

• Shinzato Toru
• Maruyama Yasuyo
• Ueno Fumihiko

Classifications

• G16H20/10

  relating to drugs or medications, e.g. for ensuring correct administration to patients · CPC title

• G01N33/72 Primary

  involving blood pigments, e.g. haemoglobin, bilirubin {or other porphyrins; involving occult blood} · CPC title

• G01N33/721

  Haemoglobin · CPC title

• G16H20/17

  delivered via infusion or injection · CPC title

• G01N2333/805

  Haemoglobins; Myoglobins · CPC title